HER2/HR阳性乳腺癌治疗进展
Research Progress of HER2/HR-Positive Breast Cancer
DOI: 10.12677/ACM.2021.118562, PDF,    国家自然科学基金支持
作者: 杨 雪, 李 玲, 吴大鹏, 袁胜利*：青岛大学附属青岛市立医院，山东 青岛；刘根利：大连医科大学附属青岛大学附属青岛市立医院，山东 青岛
关键词: 乳腺癌；HER2/HR阳性；化疗；抗HER-2药物；激素治疗；CDK4/6抑制剂；Breast Cancer； Triple-Positive； Chemotherapy； Anti-Her-2 Treatment； Hormone Therapy； CDK4/6 Inhibitors
摘要: 乳腺癌是一种异质性疾病，在HER-2阳性亚型中，由于存在大量的表型和临床异质性(主要与激素受体(HR)表达有关)，这种现象得到了大量数据证明。众所周知，HER-2阳性通常与更具攻击性的肿瘤表型和降低的总生存率有关，而且与内分泌治疗的获益减少有关。临床前研究证实了HER-2和雌激素受体(ER)信号转导的功能性串扰在内分泌抵抗中的作用，同时，ER信号转导也成为对HER-2阻断剂耐药的可能机制。在HER-2阳性肿瘤中，HR状况定义了两种不同的亚型，临床行为不同，对抗癌药的敏感性也不同。三重阳性亚型，即ER/PgR/Her-2阳性肿瘤，可以被认为是最类似于HER-2阴性/HR阳性肿瘤的亚型，生物学和临床结局具有实质性差异。我们认为可以考虑在该亚组中降级治疗，即对小肿瘤，低肿瘤负荷，两种激素受体高表达的肿瘤多重靶向治疗的去化学治疗，本文回顾了有关HER-2/HR阳性肿瘤的生物学和临床数据的现有文献，试图更好地定义HER-2亚型并优化HER-2靶向药物，化学疗法，内分泌治疗和细胞周期抑制剂在各个肿瘤亚型中的应用。
Abstract: Breast cancer is a heterogeneous disease, which has been largely demonstrated in the HER-2 positive subtype due to a large number of phenotypes and clinical heterogeneity (mainly related to hormone receptor (HR) expression). It is well known that HER-2 positive is generally associated with a more aggressive tumor phenotype and reduced overall survival, and with reduced benefits from endocrine therapy. Preclinical studies have confirmed the role of functional cross-talking of HER-2 and estrogen receptor (ER) signal transduction in endocrine resistance, and ER signal transduction has also become a possible mechanism for resistance to HER-2 blockers. In HER-2 positive tumors, HR status may define two different subtypes with different clinical behaviors and different sensitivity to anticancer drugs. Triple positive subtypes, namely ER/PgR/HER-2 positive tumors, can be considered the subtypes most similar to HER-2 negative/HR positive tumors, with substantial differences in biological and clinical outcomes. We think that in some cases, whether can consider to use de-escalation therapy is taken into account in the subgroups, namely for small tumors, low tumor load, two kinds of hormone receptor targeted therapy of high expression of multiple tumor to chemotherapy. This paper reviewed about its HER-2/ER/PgR positive tumor biology and clinical data of the existing literature, in an attempt to better define its HER-2 subtypes and optimize its HER-2 targeted drugs, chemotherapy, endocrine therapy and CDK4/6 inhibitors in the application of different tumor subtypes.
文章引用：杨雪, 李玲, 刘根利, 吴大鹏, 袁胜利. HER2/HR阳性乳腺癌治疗进展[J]. 临床医学进展, 2021, 11(8): 3835-3847. https://doi.org/10.12677/ACM.2021.118562

参考文献

[1] Griguolo, G., Holgado, E., Cortes, J., Fasani, R., Pascual, T., Paré, L., et al. (2019) Abstract P6-17-08: Dynamics of Tumor-Infiltrating Lymphocytes (TILs) during Neoadjuvant Dual HER2 Blockade in HER2-Positive (HER2+) Breast Cancer in the Absence of Chemotherapy. Cancer Research, 79, P6-17-08. [Google Scholar] [CrossRef] 
[2] Perou, C.M., Sorlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., et al. (2000) Molecular Portraits of Human Breast Tumours. Nature, 406, 747-752. [Google Scholar] [CrossRef] [PubMed]
[3] Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A. and McGuire, W.L. (1987) Human-Breast Cancer—Correlation of Relapse and Survival with Amplification of the HER-2 Neu Oncogene. Science, 235, 177-182. [Google Scholar] [CrossRef] [PubMed]
[4] Knauer, M., Cardoso, F., Wesseling, J., Bedard, P.L., Linn, S.C., Rutgers, E.J.T., et al. (2010) Identification of a Low-Risk Subgroup of HER-2-Positive Breast Cancer by the 70-Gene Prognosis Signature. British Journal of Cancer, 103, 1788-1793. [Google Scholar] [CrossRef] [PubMed]
[5] Konecny, G., Pauletti, G., Pegram, M., Bedard, P.L., Linn, S.C., Rutgers, E.J.T., et al. (2003) Quantitative Association between, HER-2/Neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer. Journal of the National Cancer Institute, 95, 142-153. [Google Scholar] [CrossRef] [PubMed]
[6] Lal, P., Tan, L.K. and Chen, B.Y. (2005) Correlation of HER-2 Status with Estrogen and Progesterone Receptors and Histologic Features in 3,655 Invasive Breast Carcinomas. American Journal of Clinical Pathology, 123, 541-546. [Google Scholar] [CrossRef] 
[7] Dowsett, M., Allred, C., Knox, J., Quinn, E., Salter, J., Wale, C., et al. (2008) Relationship between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status with Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. Journal of Clinical Oncology, 26, 1059-1065. [Google Scholar] [CrossRef] 
[8] Omarini, C., Bettelli, S., Caprera, C., Manfredini, S., Barbolini, M., Moscetti, L., et al. (2019) Differential Molecular Pathways Expression in HER2 Positive Early Breast Cancer According to Hormone Receptor Status. Journal of Cancer Research and Clinical Oncology, 145, 821-828. [Google Scholar] [CrossRef] [PubMed]
[9] Guo, L., Zhu, Q., Aisimutuola, M., Yilamu, D., Liu, S. and Jakulin, A. (2015) Expression and Prognostic Value of Estrogen Receptor Beta in Patients with Triple-Negative and Triple-Positive Breast Cancer. Experimental and Therapeutic Medicine, 9, 2147-2150. [Google Scholar] [CrossRef] [PubMed]
[10] Pinhel, I., Hills, M., Drury, S., Salter, J., Sumo, G., A’Hern, R., et al. (2012) ER and HER2 Expression Are Positively Correlated in HER2 Non-Overexpressing Breast Cancer. Breast Cancer Research, 14, Article No. R46. [Google Scholar] [CrossRef] [PubMed]
[11] Yang, H.-Y., Ma, D., Liu, Y.-R., Hu, X., Zhang, J., Wang, Z.-H., et al. (2018) Impact of Hormone Receptor Status and Distant Recurrence-Free Interval on Survival Benefits from Trastuzumab in HER2-Positive Metastatic Breast Cancer. Scientific Reports, 7, Article No. 1134. [Google Scholar] [CrossRef] [PubMed]
[12] Cortes, J. and Baselga, J. (2009) How to Treat Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Amplified Breast Cancer. Journal of Clinical Oncology, 27, 5492-5494. [Google Scholar] [CrossRef] 
[13] Llombart-Cussac, A., Cortes, J., Pare, L., Galván, P., Bermejo, B., Martínez, N., et al. (2017) HER2-Enriched Subtype as a Predictor of Pathological Complete Response Following Trastuzumab and Lapatinib without Chemotherapy in Early-Stage HER2-Positive Breast Cancer (PAMELA): An Open-Label, Single-Group, Multicentre, Phase 2 Trial. The Lancet Oncology, 18, 545-554. [Google Scholar] [CrossRef] 
[14] Prat, A., Bianchini, G., Thomas, M., Belousov, A., Cheang, M.C.U., Koehler, A., et al. (2014) Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study. Clinical Cancer Research, 20, 511-521. [Google Scholar] [CrossRef] 
[15] Prat, A., Pascual, T. and Adamo, B. (2017) Intrinsic Molecular Subtypes of HER2+ Breast Cancer. Oncotarget, 8, 73362-73363. [Google Scholar] [CrossRef] [PubMed]
[16] Lambertini, M., Campbell, C., Gelber, R.D., Viale, G., McCullough, A., Hilbers, F., et al. (2019) Dissecting the Effect of Hormone Receptor Status in Patients with HER2-Positive Early Breast Cancer: Exploratory Analysis from the ALTTO (BIG 2-06) Randomized Clinical Trial. Breast Cancer Research and Treatment, 177, 103-114. [Google Scholar] [CrossRef] [PubMed]
[17] Anderson, W.F., Chatterjee, N., Ershler, W.B. and Brawley, O.W. (2002) Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database. Breast Cancer Research and Treatment, 76, 27-36. [Google Scholar] [CrossRef] 
[18] Rakha, E.A., El-Sayed, M.E., Green, A.R., Claire Paish, E., Powe, D.G., Gee, J., et al. (2007) Biologic and Clinical Characteristics of Breast Cancer with Single Hormone Receptor-Positive Phenotype. Journal of Clinical Oncology, 25, 4772-4778. [Google Scholar] [CrossRef] 
[19] Broglio, K.R., Quintana, M., Foster, M., Olinger, M., McGlothlin, A., Berry, S.M., et al. (2016) Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer with Long-Term Outcomes A Meta-Analysis. JAMA Oncology, 2, 751-760. [Google Scholar] [CrossRef] [PubMed]
[20] The Cancer Genome Atlas Network (2012) Comprehensive Molecular Portraits of Human Breast Tumours. Nature, 490, 61-70. [Google Scholar] [CrossRef] [PubMed]
[21] Tripathy, D., Kaufman, P.A., Brufsky, A.M., Mayer, M., Yood, M.U., Yoo, B., et al. (2013) First-Line Treatment Patterns and Clinical Outcomes in Patients with HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer from RegistHER. Oncologist, 18, 501-510. [Google Scholar] [CrossRef] [PubMed]
[22] Loibl, S., De La Pena, L., Nekljudova, V., Zardavas, D., Denkert, C., Denkert, C., et al. (2017) Neoadjuvant Buparlisib plus Trastuzumab and Paclitaxel for Women with HER2+ Primary Breast Cancer: A Randomised, Double-Blind, Placebo-Controlled Phase II Trial (Neophoebe). European Journal of Cancer, 85, 133-145. [Google Scholar] [CrossRef] [PubMed]
[23] Harbeck, N., Gluz, O., Christgen, M., Braun, M., Kuemmel, S., Schumacher, C., et al. (2016) Abstract S5-03: Final Analysis of WSG-ADAPT HER2+/HR+ Phase II Trial: Efficacy, Safety, and Predictive Markers for 12-Weeks of Neoadjuvant TDM1 with or without Endocrine Therapy versus Trastuzumab plus Endocrine Therapy in HER2-Positive Hormone-Receptor Positive Early Breast Cancer. Cancer Research, 76, S5-03. [Google Scholar] [CrossRef] 
[24] Untch, M., Loibl, S., Bischoff, J., Eidtmann, H., Kaufmann, M., Blohmer, J.-U., et al. (2012) Lapatinib versus Trastuzumab in Combination with Neoadjuvant Anthracycline-Taxane-Based Chemotherapy (GeparQuinto, GBG 44): A Randomised Phase 3 Trial. The Lancet Oncology, 13, 135-144. [Google Scholar] [CrossRef] 
[25] Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., Aura, C., De Azambuja, E., et al. (2010) Abstract S3-3: First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer. Cancer Research, 70, S3-3. [Google Scholar] [CrossRef] 
[26] Hurvitz, S.A., Martin, M., Jung, K.H., Huang, C.-S., Harbeck, N., et al. (2019) Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes from the Phase III Kristine Study. Journal of Clinical Oncology, 37, 2206-2216. [Google Scholar] [CrossRef] 
[27] Gianni, L., Pienkowski, T., Im, Y.-H., Tseng, L.-M., Liu, M.-C., Lluch, A., et al. (2016) 5-Year Analysis of Neoadjuvant Pertuzumab and Trastuzumab in Patients with Locally Advanced, Inflammatory, or Early-Stage HER2-Positive Breast Cancer (NeoSphere): A Multicentre, Open-Label, Phase 2 Randomised Trial. The Lancet Oncology, 17, 791-800. [Google Scholar] [CrossRef] 
[28] Cantini, L., Pistelli, M., Merloni, F., Fontana, A., Bertolini, I., De Angelis, C., et al. (2020) Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients. Clinical Breast Cancer, 20, E89-E98. [Google Scholar] [CrossRef] [PubMed]
[29] Nitz, U.A., Gluz, O., Christgen, M., Grischke, E.-M., Augustin, D., Kuemmel, S., et al. (2017) De-Escalation Strategies in HER2-Positive Early Breast Cancer (EBC): Final Analysis of the WSG-ADAPT HER2+/HR− Phase II Trial: Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Dual Blockade with Trastuzumab and Pertuzumab ± Weekly Paclitaxel. Annals of Oncology, 28, 2768-2772. [Google Scholar] [CrossRef] [PubMed]
[30] Gianni, L., Eiermann, W., Semiglazov, V., Manikhas, A., Lluch, A., Tjulandin, S., et al. (2013) Follow-Up Results of NOAH, a Randomized Phase III Trial Evaluating Neoadjuvant Chemotherapy with Trastuzumab (CT+H) Followed by Adjuvant H versus CT Alone, in Patients with HER2-Positive Locally Advanced Breast Cancer. Journal of Clinical Oncology, 31, 503. [Google Scholar] [CrossRef] 
[31] Hurvitz, S.A., Martin, M., Symmans, W.F., Jung, K.H., Huang, C.-S., et al. (2018) Neoadjuvant Trastuzumab, Pertuzumab, and Chemotherapy versus Trastuzumab Emtansine Plus Pertuzumab in Patients with HER2-Positive Breast Cancer (KRISTINE): A Randomised, Open-Label, Multicentre, Phase 3 Trial. The Lancet Oncology, 19, 115-126. [Google Scholar] [CrossRef] 
[32] Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Hegg, R., et al. (2013) Pertuzumab Plus Trastuzumab in Combination with Standard Neoadjuvant Anthracycline-Containing and Anthracycline-Free Chemotherapy Regimens in Patients with HER2-Positive Early Breast Cancer: A Randomized Phase II Cardiac Safety Study (Tryphaena). Annals of Oncology, 24, 2278-2284. [Google Scholar] [CrossRef] [PubMed]
[33] Untch, M., Von Minckwitz, G., Gerber, B., Schem, C., Rezai, M., Fasching, P.A., et al. (2018) Survival Analysis after Neoadjuvant Chemotherapy with Trastuzumab or Lapatinib in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). Journal of Clinical Oncology, 36, 1308-1316. [Google Scholar] [CrossRef] 
[34] Rimawi, M.F., Mayer, I.A., Forero, A., Nanda, R., Goetz, M.P., Rodriguez, A.A., et al. (2013) Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab with Hormonal Therapy and without Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: TBCRC 006. Journal of Clinical Oncology, 31, 1726-1731. [Google Scholar] [CrossRef] 
[35] Sudhan, D.R., Schwarz, L.J., Guerrero-Zotano, A., Formisano, L., Nixon, M.J., Croessmann, S., et al. (2019) Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. Clinical Cancer Research, 25, 771-783. [Google Scholar] [CrossRef] 
[36] Cameron, D., Piccart-Gebhart, M.J., Gelber, R.D., Procter, M., Goldhirsch, A., de Azambuja, E., et al. (2017) 11 Years’ Follow-Up of Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Early Breast Cancer: Final Analysis of the HERceptin Adjuvant (HERA) Trial. Lancet, 389, 1195-1205. [Google Scholar] [CrossRef] 
[37] Piccart-Gebhart, M.J., Holmes, A.P., Baselga, J., De Azambuja, E., Dueck, A.C., Viale, G., et al. (2014) First Results from the Phase III ALTTO Trial (BIG 2-06; NCCTG Alliance N063D) Comparing One Year of Anti-HER2 Therapy with Lapatinib alone (L), Trastuzumab Alone (T), Their Sequence (T → L), or Their Combination (T Plus L) in the Adjuvant Treatment of HER2-Positive Early Breast Cancer (EBC). Journal of Clinical Oncology, 32, LBA4. [Google Scholar] [CrossRef] 
[38] Goldhirsch, A., Gelber, R.D., Piccart-Gebhart, M.J., de Azambuja, E., Procter, M., Suter, T.M., et al. (2013) 2 Years versus 1 Year of Adjuvant Trastuzumab for HER2-Positive Breast Cancer (HERA): An Open-Label, Randomised Controlled Trial. Lancet, 382, 1021-1028. [Google Scholar] [CrossRef] 
[39] Moreno-Aspitia, A., Holmes, E.M., Jackisch, C., De Azambuja, E., Boyle, F., Hillman, D.W., et al. (2017) Updated Results from the Phase III ALTTO Trial (BIG 2-06; NCCTG (Alliance) N063D) Comparing One Year of Anti-HER2 Therapy with Lapatinib Alone (L), Trastuzumab Alone (T), Their Sequence (T → L) or Their Combination (L + T) in the Adjuvant Treatment of HER2-Positive Early Breast Cancer. Journal of Clinical Oncology, 35, 502-502. [Google Scholar] [CrossRef] 
[40] Martin, M., Holmes, F.A., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., et al. (2017) Neratinib After Trastuzumab-Based Adjuvant Therapy in HER2-Positive Breast Cancer (ExteNET): 5-Year Analysis of a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet Oncology, 18, 1688-1700. [Google Scholar] [CrossRef] 
[41] Chan, A., Delaloge, S., Holmes, F.A., Moy, B., Iwata, H., Harvey, V.J., et al. (2016) Neratinib after Trastuzumab-Based Adjuvant Therapy in Patients with HER2-Positive Breast Cancer (ExteNET): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet Oncology, 17, 367-377. [Google Scholar] [CrossRef] 
[42] Johnston, S.R.D., Hegg, R., Im, S.A., Park, I.H., Burdaeva, O., Kurteva, G., et al. (2018) Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade with Lapatinib Plus Trastuzumab in Combination with an Aromatase Inhibitor in Postmenopausal Women with HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE. Journal of Clinical Oncology, 36, 741-748. [Google Scholar] [CrossRef] 
[43] Krop, I.E., Lin, N.U., Blackwell, K., Guardino, E., Huober, J., Lu, M., et al. (2015) Trastuzumab Emtansine (T-DM1) versus Lapatinib Plus Capecitabine in Patients with HER2-Positive Metastatic Breast Cancer and Central Nervous System Metastases: A Retrospective, Exploratory Analysis in EMILIA. Annals of Oncology, 26, 113-119. [Google Scholar] [CrossRef] [PubMed]
[44] Swain, S.M., Kim, S.B., Cortes, J., Ro, J., Semiglazov, V., Campone, M., et al. (2013) Pertuzumab, Trastuzumab, and Docetaxel for HER2-Positive Metastatic Breast Cancer (CLEOPATRA Study): Overall Survival Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study. Lancet Oncology, 14, 461-471. [Google Scholar] [CrossRef] 
[45] Arpino, G., Ferrero, J.M., De La Haba-Rodriguez, J., Easton, V., Schuhmacher, C., Restuccia, E., et al. (2017) Abstract S3-04: Primary Analysis of Pertain: A Randomized, Two-Arm, Open-Label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination with Trastuzumab Plus an Aromatase Inhibitor in First-Line Patients with HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer. Cancer Research, 77, S3-04. [Google Scholar] [CrossRef] 
[46] Dieras, V., Miles, D., Verma, S., Pegram, M., Welslau, M., Baselga, J., et al. (2017) Trastuzumab Emtansine versus Capecitabine Plus Lapatinib in Patients with Previously Treated HER2-Positive Advanced Breast Cancer (EMILIA): A Descriptive Analysis of Final Overall Survival Results from A Randomised, Open-Label, Phase 3 Trial. Lancet Oncology, 18, 732-742. [Google Scholar] [CrossRef] 
[47] Tolaney, S.M., Wardley, A.M., Zambelli, S., Hilton, J.F., Troso-Sandoval, T.A., Ricci, F., et al. (2020) Abemaciclib Plus Trastuzumab with or without Fulvestrant versus Trastuzumab Plus Standard-of-Care Chemotherapy in Women with Hormone Receptor-Positive, HER2-Positive Advanced Breast Cancer (MonarcHER): A Randomised, Open-Label, Phase 2 Trial. The Lancet Oncology, 21, 763-775. [Google Scholar] [CrossRef] 
[48] Perez, E.A., Hurvitz, S.A., Amler, L.C., Mundt, K.E., Ng, V., Guardino, E., et al. (2014) Relationship between HER2 Expression and Efficacy with First-Line Trastuzumab Emtansine Compared with Trastuzumab Plus Docetaxel in TDM4450g: A Randomized Phase II Study of Patients with Previously Untreated HER2-Positive Metastatic Breast Cancer. Breast Cancer Research, 16, Article No. R50. [Google Scholar] [CrossRef] [PubMed]
[49] Burstein, H.J., Cirrincione, C.T., Barry, W.T., Chew, H.K., Tolaney, S.M., Lake, D.E., et al. (2014) Endocrine Therapy with or without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant with or without Lapatinib for Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer—CALGB 40302 (Alliance). Journal of Clinical Oncology, 32, 3959-3966. [Google Scholar] [CrossRef] 
[50] Toi, M., Shao, Z., Hurvitz, S., Tseng, L.-M., Zhang, Q., Shen, K., et al. (2017) Efficacy and Safety of Everolimus in Combination with Trastuzumab and Paclitaxel in Asian Patients with HER2+ Advanced Breast Cancer in BOLERO-1. Breast Cancer Research, 19, Article No. 47. [Google Scholar] [CrossRef] [PubMed]
[51] Rimawi, M., Ferrero, J.-M., De La Haba-Rodriguez, J., Poole, C., De Placido, S., Kent Osborne, C., et al. (2018) First-Line Trastuzumab Plus an Aromatase Inhibitor, with or without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. Journal of Clinical Oncology, 36, 2826-2835. [Google Scholar] [CrossRef] 
[52] Krop, I.E., Kim, S.B., Martin, A.G., LoRusso, P.M., Ferrero, J.-M., Badovinac-Crnjevic, T., et al. (2017) Trastuzumab Emtansine versus Treatment of Physician’s Choice in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer (TH3RESA): Final Overall Survival Results from a Randomised Open-Label Phase 3 Trial. The Lancet Oncology, 18, 743-754. [Google Scholar] [CrossRef] 
[53] Perez, E.A., Barrios, C., Eiermann, W., Toi, M., Im, Y.-H., Conte, P., et al. (2017) Trastuzumab Emtansine with or without Pertuzumab versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results from the Phase III MARIANNE Study. Journal of Clinical Oncology, 35, 141-148. [Google Scholar] [CrossRef] 
[54] Krop, I.E., Kim, S.-B., Gonzalez Martin, A., LoRusso, P.M., Ferrero, J.-M., Badovinac-Crnjevic, T., et al. (2017) Trastuzumab Emtansine versus Treatment of Physician’s Choice in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer (TH3RESA): Final Overall Survival Results from a Randomised Open-Label Phase 3 Trial. The Lancet Oncology, 18, 743-754. [Google Scholar] [CrossRef] 
[55] Krop, I.E., Kim, S.-B., Gonzalez-Martin, A., LoRusso, P.M., Ferrero, J.-M., Smitt, M., et al. (2014) Trastuzumab Emtansine versus Treatment of Physician’s Choice for Pretreated HER2-Positive Advanced Breast Cancer (TH3RESA): A Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 15, 689-699. [Google Scholar] [CrossRef] 
[56] Wilson, T.R., Yu, J., Lu, X., Spoerke, J.M., Xiao, Y., O’Brien, C., et al. (2016) The Molecular Landscape of High-Risk Early Breast Cancer: Comprehensive Biomarker Analysis of a Phase III Adjuvant Population. NPJ Breast Cancer, 2, Article No. 16022. [Google Scholar] [CrossRef] [PubMed]
[57] Herrera-Abreu, M.T., Palafox, M., Asghar, U., Rivas, M.A., Cutts, R.J., Garcia-Murillas, I., et al. (2016) Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. Cancer Research, 76, 2301-2313. [Google Scholar] [CrossRef] 
[58] Scaltriti, M., Eichhorn, P.J., Cortes, J., Prudkin, L., Aura, C., Jiménez, J., et al. (2011) Cyclin E Amplification/Overexpression Is a Mechanism of Trastuzumab Resistance in HER2+ Breast Cancer Patients. Proceedings of the National Academy of Sciences of the United States of America, 108, 3761-3766. [Google Scholar] [CrossRef] [PubMed]

为你推荐